Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.52 |
| ▸ | STAT3 | P40763 | 7/20 | 0.49 |
| ▸ | GIPR | P48546 | 5/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | STAT5B | P51692 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666417 | 0.94 | STAT3 (0.48) | GCGRSTAT3GIPRSTAT1STAT5B | |
| SCHEMBL2653454 | 0.91 | GCGR (0.63) | GCGRSTAT3GIPROPRM1OPRK1 | |
| SCHEMBL2654610 | 0.90 | GCGR (0.66) | GCGRSTAT3GIPR | |
| SCHEMBL2656083 | 0.87 | GCGR (0.59) | GCGRSTAT3GIPROPRM1OPRK1 | |
| SCHEMBL2654233 | 0.85 | GCGR (0.58) | GCGRSTAT3GIPR | |
| SCHEMBL2656208 | 0.83 | GCGR (0.54) | GCGRGIPR | |
| SCHEMBL2666459 | 0.82 | GCGR (0.64) | GCGRSTAT3GIPR | |
| SCHEMBL9072847 | 0.81 | GCGR (0.67) | GCGRSTAT3GIPR | |
| SCHEMBL4094162 | 0.80 | GCGR (0.62) | GCGRSTAT3GIPROPRM1OPRK1 | |
| SCHEMBL2659718 | 0.80 | GCGR (0.55) | GCGRSTAT3GIPROPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885STAT3 1711/4885GIPR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.